Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Exelixis (EXEL) beats on earnings and sales in the second quarter.
, /PRNewswire/ -- The report has been added to offering.
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.
Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.
, /PRNewswire/ --Read the full report: The Global Colorectal Cancer Drugs Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 3.94%.Market Segmentation...
, /PRNewswire/ -- The drug pipelines has been added to offering.
- COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing -
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Global growth equity investor Summit Partners today announced the addition of Brian Kim to the firm's Executive-in-Residence ("EIR") program. In this role, Mr. Kim will work closely with Summit's healthcare...
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition...
report by Marketinsightsreports offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Clostridium Difficile Infections (Clostridium Difficile...
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries......
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development,...